The FREEDOM trial is a 36-month international RCT of 7,868 postmenopausal women with osteoporosis (T-score −2.5 to −4.0) testing whether subcutaneous denosumab 60 mg every 6 months reduces fracture risk compared to placebo across vertebral, hip, and nonvertebral sites.
The FREEDOM trial is a 36-month international RCT of 7,868 postmenopausal women with osteoporosis (T-score −2.5 to −4.0) testing whether subcutaneous denosumab 60 mg every 6 months reduces fracture risk compared to placebo across vertebral, hip, and nonvertebral sites.